MCL1 and cancer: Current efforts are aimed at developing effective and tolerable treatment schedules for the BH3-mimetic drugs that inhibit MCL-1 or BCL-XL and to discover which other anti-cancer agents can be combined with these drugs to achieve effective and safe cancer therapy.